on 17 September 2026, AI chip stocks traded with volatility and pulled back, with ASMPT (00522.HK) weakening. As of 13:45, the company quoted HKD 158.000, down 2.05%.
on 17 September 2026, humanoid robot stocks strengthened while XIAOMI-W (01810.HK) weakened. As of 13:24, the company quoted HKD 25.900, down 1.07%.
On 16 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that the 24-week treatment data observation of the China Phase I clinical study of its self-developed candidate drug molecule HX9428 for the treatment of neovascular age-related macular degeneration (nAMD) has been completed, while the Phase II dose expansion study is ongoing with interim data obtained; among the 13 patients who completed 24 weeks of treatment in Phase I, BCVA improved by an average of 5.2 letters from baseline and CST decreased by an average of 73.3 μm.
On 16 September 2026, CSPC PHARMA (01093.HK) announced that the Phase II clinical trial (SYH2069-003) of SYH2069 injection, developed by the Group, for the treatment of adult type 2 diabetes has formally commenced at the first study site in China.
On 16 September 2026, HANSOH PHARMA (03692.HK) announced that HS-20197 for injection, a Class 1 innovative drug independently developed by the Group, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026, for the conduct of clinical trials in "advanced solid tumours".
On 16 September 2026, SSY GROUP (02005.HK) announced that the Group's ziprasidone mesylate has been approved by the National Medical Products Administration of the PRC for registration as an active pharmaceutical ingredient for use in marketed formulations, mainly for the treatment of acute agitation in patients with schizophrenia.
On September 16, 2026, the three major Hong Kong indices opened higher and moved in a choppy range, with the Hang Seng Index up 0.19%, the Hang Seng TECH Index up 0.79%, and the Hang Seng China Enterprises Index up 0.02%.AI concept stocks diverged on the day, with the AI Chips sector surging collectively, the LLM sector mixed, and most Autonomous Driving stocks weakening.
On September 16, 2026, RoboSense (02498.HK) edged higher in the afternoon. As of 14:03, the stock was quoted at HK$16.16, up 1.32%.
on 16 September 2026, AI chip stocks strengthened, with SMIC (00981.HK) strengthening as well. As of 13:36, the company quoted HKD 63.200, up 4.03%.
on 16 September 2026, humanoid robot stocks traded actively while UBTECH ROBOTICS (09880.HK) strengthened. As of 13:25, the company quoted HKD 77.550, up 1.11%.
On 15 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Fujian Shengdi Pharmaceutical received a Drug Clinical Trial Approval Notice from the NMPA approving a clinical trial of HRS-4139 tablets in moderate-to-severe plaque psoriasis.
On 15 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceuticals received a Drug Clinical Trial Approval Notice from the NMPA approving a Phase III clinical trial of recaticimab for injection in adult patients with intracranial atherosclerotic stenosis.
On 16 September 2026, SBP GROUP (01177.HK) announced that the NDA for TQH2722 injection (an IL-4Rα monoclonal antibody), a National Class 1 innovative drug independently developed by its subsidiary Chia Tai Tianqing, has been accepted for review by the CDE, for moderate-to-severe atopic dermatitis in adults.
On 16 September 2026, SBP GROUP (01177.HK) announced that the NDA for TQB2102 injection (a HER2 biparatopic bispecific ADC), a National Class 1 innovative drug independently developed by its subsidiary Chia Tai Tianqing, has been accepted for review by the CDE, for HER2-low breast cancer in adults.
On 15 September 2026, Suzhou Basecare Medical Corporation Limited (02170.HK) announced that the freezing solution kit and the thawing solution kit of its Gems vitrification series have recently obtained Class III medical device registration certificates issued by the National Medical Products Administration; the products originate from the same research and development system as the Gavi fully automated closed vitrification system.
On 15 September 2026, CSPC PHARMA (01093.HK) announced that SYS6010, developed by the Group, has been included by the National Medical Products Administration of the PRC in the breakthrough therapy designation list, for the proposed indication of relapsed or metastatic driver-gene-negative non-squamous non-small cell lung cancer in patients who have failed prior immunotherapy and platinum-containing chemotherapy.
